Soleno Therapeutics (SLNO) News Today $67.48 -4.68 (-6.49%) Closing price 04:00 PM EasternExtended Trading$67.53 +0.05 (+0.07%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Patricia C. Hirano Sells 3,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Patricia C. Hirano sold 3,782 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $70.11, for a total transaction of $265,156.02. Following the completion of the sale, the insider now directly owns 27,036 shares of the company's stock, valued at $1,895,493.96. The trade was a 12.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.April 4 at 7:23 PM | marketbeat.comHC Wainwright Issues Optimistic Estimate for SLNO EarningsApril 4 at 1:21 AM | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Shares Down 6.7% After Insider SellingSoleno Therapeutics (NASDAQ:SLNO) Trading Down 6.7% Following Insider SellingApril 3 at 2:18 PM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $265,156.02 in StockApril 3 at 5:38 AM | insidertrades.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Down 6.7% on Insider SellingApril 3 at 2:16 AM | americanbankingnews.comWinners and wishers: 8 potential Bay Area drug approvals coming this yearApril 2 at 10:25 AM | bizjournals.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, HC Wainwright Analyst SaysApril 2 at 3:02 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls Sells 5,937 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) Director Matthew Pauls sold 5,937 shares of the business's stock in a transaction dated Friday, March 28th. The shares were sold at an average price of $71.55, for a total value of $424,792.35. Following the transaction, the director now owns 6,500 shares in the company, valued at approximately $465,075. This represents a 47.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.April 1 at 10:22 PM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) VP Sells $1,013,664.33 in StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) VP Michael F. Huang sold 14,583 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.51, for a total transaction of $1,013,664.33. Following the sale, the vice president now owns 36,817 shares in the company, valued at $2,559,149.67. This represents a 28.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.April 1 at 10:22 PM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness Sells 90,622 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) CFO James H. Mackaness sold 90,622 shares of the business's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.44, for a total transaction of $6,292,791.68. Following the completion of the sale, the chief financial officer now owns 105,176 shares of the company's stock, valued at approximately $7,303,421.44. The trade was a 46.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.April 1 at 10:22 PM | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 128,653 Shares of StockSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Patricia C. Hirano sold 128,653 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the transaction, the insider now owns 55,789 shares in the company, valued at $3,811,504.48. The trade was a 69.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.April 1 at 7:36 PM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 699,095 SharesSoleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) CEO Bhatnagar Anish sold 699,095 shares of the firm's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now directly owns 577,076 shares of the company's stock, valued at $39,021,879.12. The trade was a 54.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.April 1 at 7:36 PM | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume After Analyst UpgradeSoleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume on Analyst UpgradeApril 1 at 11:34 AM | marketbeat.comSoleno Therapeutics price target raised to $100 from $70 at H.C. WainwrightApril 1 at 11:02 AM | markets.businessinsider.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $100.00HC Wainwright raised their price target on Soleno Therapeutics from $70.00 to $100.00 and gave the stock a "buy" rating in a report on Monday.April 1 at 8:19 AM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Pictet Asset Management Holding SAPictet Asset Management Holding SA raised its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 48.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 851,838 shares of the company's stock after buyiApril 1 at 4:32 AM | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Sells $424,792.35 in StockApril 1 at 4:19 AM | insidertrades.comSLNO FY2025 EPS Forecast Reduced by Cantor FitzgeraldApril 1 at 3:07 AM | americanbankingnews.comQ1 EPS Forecast for Soleno Therapeutics Decreased by AnalystApril 1 at 1:17 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Rating of "Buy" by AnalystsMarch 31, 2025 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Rating of "Buy" from AnalystsShares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been assigned an average rating of "Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two hMarch 31, 2025 | marketbeat.comFY2025 EPS Estimates for SLNO Reduced by Cantor FitzgeraldSoleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Soleno Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska now anticMarch 31, 2025 | marketbeat.comWhat is Lifesci Capital's Forecast for SLNO Q1 Earnings?Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities research analysts at Lifesci Capital lowered their Q1 2025 earnings per share estimates for Soleno Therapeutics in a report released on Thursday, March 27th. Lifesci Capital analyst M. Belghiti now anticipates that the company willMarch 31, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $108.00March 30, 2025 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Up 3.9% Following Analyst UpgradeMarch 30, 2025 | americanbankingnews.comWhy Soleno Therapeutics Inc. (SLNO) Went Up Last Week?March 30, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Given New $108.00 Price Target at Stifel NicolausStifel Nicolaus upped their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday.March 29, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Shares Up 3.9% on Analyst UpgradeSoleno Therapeutics (NASDAQ:SLNO) Shares Up 3.9% on Analyst UpgradeMarch 29, 2025 | marketbeat.comSoleno Therapeutics price target raised to $108 from $74 at StifelMarch 29, 2025 | markets.businessinsider.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, Cantor Fitzgerald Analyst SaysMarch 29, 2025 | americanbankingnews.comRobert W. Baird Increases Soleno Therapeutics (NASDAQ:SLNO) Price Target to $102.00March 29, 2025 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year High After Analyst UpgradeMarch 29, 2025 | americanbankingnews.comUS FDA approves first treatment for rare genetic disorder Prader-Willi syndromeMarch 28, 2025 | msn.comSoleno Therapeutics price target raised to $81 from $70 at GuggenheimMarch 28, 2025 | markets.businessinsider.comWhy Soleno Therapeutics Inc. (SLNO) Surged On Thursday?March 28, 2025 | msn.comWhy Soleno Therapeutics Inc. (SLNO) Went Up On Friday?March 28, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $105.00 at LaidlawLaidlaw lifted their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a research note on Thursday.March 28, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 52-Week High After Analyst UpgradeSoleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month High After Analyst UpgradeMarch 28, 2025 | marketbeat.comCantor Fitzgerald Forecasts Strong Price Appreciation for Soleno Therapeutics (NASDAQ:SLNO) StockCantor Fitzgerald boosted their target price on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the company an "overweight" rating in a research note on Thursday.March 28, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $102.00Robert W. Baird raised their target price on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday.March 28, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $105.00March 28, 2025 | americanbankingnews.comSwiss National Bank Grows Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)Swiss National Bank grew its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 27.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,900 shares of the company's stock after purchasing an additionMarch 28, 2025 | marketbeat.comSoleno wins FDA approval for Prader-Willi hyperphagia treatmentMarch 27, 2025 | finance.yahoo.comSoleno Therapeutics (SLNO) Receives a New Rating from Cantor FitzgeraldMarch 27, 2025 | markets.businessinsider.comSoleno Shares Are Up Today: What's Going On?March 27, 2025 | benzinga.comSoleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat ApprovalMarch 27, 2025 | seekingalpha.comSoleno Therapeutics execs reap stock windfall after FDA approves rare disease drugMarch 27, 2025 | bizjournals.com5SLNO : Behind the Scenes of Soleno Therapeutics'...March 27, 2025 | benzinga.comSoleno Stock (SLNO) Soars 32% after FDA Greenlights New DrugMarch 27, 2025 | markets.businessinsider.comSoleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment PeaksMarch 27, 2025 | msn.com Remove Ads Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Media Mentions By Week SLNO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLNO News Sentiment▼0.330.61▲Average Medical News Sentiment SLNO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLNO Articles This Week▼505▲SLNO Articles Average Week Remove Ads Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Smith & Nephew News Penumbra News Stevanato Group News Glaukos News Bausch + Lomb News Inspire Medical Systems News Inari Medical News iRhythm Technologies News PROCEPT BioRobotics News Envista News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLNO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLNO Stock Free SLNO Stock Alerts